{"id":"hs-10234","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Stomatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HS-10234 targets FGFR mutations and fusions that drive proliferation in certain solid tumors. By inhibiting FGFR kinase activity, the drug suppresses downstream signaling pathways critical for tumor cell survival and growth. This mechanism is particularly relevant in cancers with FGFR alterations, including cholangiocarcinoma and other FGFR-driven malignancies.","oneSentence":"HS-10234 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:59.031Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR-altered solid tumors (including cholangiocarcinoma and other FGFR-driven cancers)"}]},"trialDetails":[{"nctId":"NCT06743438","phase":"PHASE4","title":"Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2022-03-10","conditions":"Hepatitis B, Chronic","enrollment":640},{"nctId":"NCT03903796","phase":"PHASE3","title":"Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2018-08-16","conditions":"Chronic HBV Infection","enrollment":963},{"nctId":"NCT04477096","phase":"PHASE1","title":"Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine","status":"COMPLETED","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2020-08-03","conditions":"Healthy Subjects","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HS-10234","genericName":"HS-10234","companyName":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","companyId":"jiangsu-hansoh-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HS-10234 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR-altered solid tumors (including cholangiocarcinoma and other FGFR-driven cancers).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}